4-(pyridin-2-yl)phenyl acetate | 1430585-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(pyridin-2-yl)phenyl acetate
• 英文别名: (4-Pyridin-2-ylphenyl) acetate
• CAS: 1430585-67-3
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: ONORDCWQFPAGBO-UHFFFAOYSA-N

物化性质

• 沸点：
  344.2±25.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(pyridin-2-yl)phenyl acetate 在 N-溴代丁二酰亚胺(NBS) 、 苯甲酸 、 copper(I) bromide 作用下， 反应 24.0h， 以75%的产率得到
  参考文献：
  名称：

  铜介导的直接芳基C ？H卤化：控制单选择性和双选择性的策略

  摘要：

  提出了铜介导的直接芳基CH卤化的方案。通过使用酰基次卤酸盐来实现高度选择性的单卤化和二卤化，酰基次卤酸盐是由现成的羧酸和N-卤代琥珀酰亚胺（NXS； X = Br和Cl）原位生成的，作为强力卤化试剂。正确选择羧酸添加剂和溶剂对于高收率和选择性都至关重要。因此，使用廉价的铜催化剂和从容易负担得起且易于处理的羧酸和NXS（X = Br和Cl）原位生成酰基次卤酸盐卤化试剂的新策略为实际应用提供了优势。

  DOI：

  10.1002/cctc.201300734
• 作为产物：
  描述：

  2-溴吡啶 、 4-乙酰氧基苯基硼酸 在 palladium diacetate 、 三苯基膦 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 4-(pyridin-2-yl)phenyl acetate
  参考文献：
  名称：

  Palladium catalyzed ortho-C–H-benzoxylation of 2-arylpyridines using iodobenzene dibenzoates

  摘要：

  A palladium-catalyzed ortho-C-H-benzoxylation of 2-arylpyridines using iodobenzene dibenzoates has been developed. The reaction employed the stable and easily accessible hypervalent iodine reagents as both benzoxylate source and oxidant which made the protocol simple and facile. It showed high regioselectivity and good functional group tolerance, and gave the mono-benzoxylation products in moderate to excellent yields. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.09.097

文献信息

• Lewis Acid/Brønsted Acid Controlled Pd(II)-Catalyzed Chemodivergent Functionalization of C(<i>sp</i>²)–H Bonds with <i>N</i>-(Arylthio)i(a)mides
  作者：Manthena Chaitanya、Pazhamalai Anbarasan

  DOI：10.1021/acs.orglett.8b01281

  日期：2018.6.1

  C–H bonds have been accomplished employing N-(arylthio)imides in combination with either Brønsted acid or Lewis acid, respectively. Notable features of the developed methodologies include excellent diversity, high functional group tolerance, wide substrate scope, and use of a single N–S reagent. Importantly, the developed hypothesis was also successfully extended to the amidation of C–H bonds. A plausible

  使用N-（芳硫基）酰亚胺分别与Brønsted酸或Lewis酸结合使用，可实现高效的化学扩散的钯催化的硫键化（CS）和酰亚胺化（CN）。所开发方法的显着特征包括出色的多样性，高官能团耐受性，广泛的底物范围以及使用单个N-S试剂。重要的是，已发展的假设也成功地扩展到C–H键的酰胺化。在初步的机理研究的基础上，提出了一条可行的机理途径。
• Rhodium(III)-Catalyzed C(<i>sp</i>²)H Activation and Electrophilic Amidation with<i>N</i>-Fluorobenzenesulfonimide
  作者：Ren-Jin Tang、Cui-Ping Luo、Luo Yang、Chao-Jun Li

  DOI：10.1002/adsc.201201133

  日期：2013.3.25

  An electrophilic amidation via a cationic rhodium(III)‐catalyzed C(sp2)H activation has been developed with the commercially available N‐fluorobenzenesulfonimide as the amino source under external oxidant‐free conditions. This amidation requires only a catalytic amount of base and exhibits excellent functional group tolerance and regioselectivity, providing a new avenue in direct C(sp2)H amidation

  在无外部氧化剂的条件下，已开发出一种通过阳离子铑（III）催化的C（sp 2）H活化进行的亲电子酰胺化反应，其中使用市售的N-氟苯磺酰亚胺作为氨基源。该酰胺化仅需催化量的碱，并表现出优异的官能团耐受性和区域选择性，为直接C（sp 2）H酰胺化提供了新途径。
• [EN] PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2000038687A1

  公开（公告）日：2000-07-06

  The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了4-氨基-氮杂丙烷-3-酮蛋白酶抑制剂及其药学上可接受的盐、水合物和溶剂化物，其能够抑制蛋白酶，包括卡他普西蛋白酶K，还提供了这些化合物的制药组合物、这些化合物的新中间体以及用于治疗过度骨质流失或软骨或基质降解等疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿性关节炎；帕吉特病；恶性高钙血症；以及代谢性骨病，通过向需要的患者施用本发明化合物来抑制骨质流失或过度软骨或基质降解。
• N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
  申请人：AiCuris GmbH & Co. KG

  公开号：EP2573085A1

  公开（公告）日：2013-03-27

  The present invention relates to the crystalline mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having the afore-mentioned particle size distribution and specific surface area range.

  本发明涉及具有一定粒度分布和比表面积范围的 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-N-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的一水甲磺酸结晶盐，该结晶盐已从药物组合物中显示出更高的长期稳定性和释放动力学、以及含有上述 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-N-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物的药物组合物，其粒度分布和比表面积范围如前所述。
• Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations
  申请人：AiCuris Anti-Infective Cures GmbH

  公开号：US10137117B2

  公开（公告）日：2018-11-27

  The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof.

  本发明涉及 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-N-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的结晶单甲磺酸一水合物盐，其粒度范围、粒度分布和比表面积范围明确，显示出更高的长期稳定性和从药物组合物中释放的动力学性能、以及含有上述结晶 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-N-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物的药物组合物，其具有上述粒度范围、粒度分布和比表面积范围。此外，本发明还涉及 N-[5-(氨基磺酰基)-4-甲基-1、此外，本发明还涉及给有需要的受试者服用上述结晶型 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-N-甲基-2-[4-(2-吡啶基)苯基]-乙酰胺甲磺酸单水合物盐后，N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-N-甲基-2-[4-(2-吡啶基)苯基]-乙酰胺的游离基的药代动力学和药效学体内曲线。